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Introduction
Psoriasis is a chronic inflammatory disease with predominant 
skin and joint involvement and a worldwide distribution affecting 
both sexes, of any age, but more frequently in the 3rd and 4th 
decades of life [1]. The disease is characterized by disfiguring 
scaling and erythematous plaques. The severity of psoriasis is 
defined by the clinical form, the proportion of body surface area 
affected and the severity of the symptoms. Psoriatic plaques may 
be painful and often severely pruritic, causing a deterioration in 
 
the quality of life [2]. Medical therapy for psoriasis has classically 
included topical and systemic treatments such as phototherapy, 
retinoids, methotrexate, and cyclosporine [3]. In the last few 
years, biologic treatment has become the established therapeutic 
standard for significant improvement of the quality of life of 
patients with moderate to severe psoriasis [4]. The involvement 
of oxidative stress in the pathogenesis of psoriasis has been 
recently proposed. Oxidative stress is an imbalance between 
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Background: Psoriasis is a worldwide chronic inflammatory disease that is increasingly being considered as a systemic disorder. Antioxidant 
and anti-inflammatory molecules have been revealed as potential adjuvants for traditional therapies.
Objectives: To evaluate the antiinflammatory action of selected antioxidant molecules and their beneficial effect as combination therapy in 
psoriatic patients. 
Materials & Methods: Thirty-five patients with mild (five), moderate (nine) and severe (twenty one) psoriasis were selected and treated 
with EP2311454 treatment. PASI, BSA and DLQI assessed the severity of psoriasis and the impact on quality of life. The antiinflammatory effect 
was tested in IFN-γ stimulated Raw264.7 macrophages that express human PPARG.
Results: The combined use in vitro of several EP2311454 components exerts a synergistic inhibitory effect on the expression of the 
proinflammatory mediators Cox2, Nos2 and Cxcl9. Clinically, more than 80% reduction in DLQI levels is observed after treatment, and 100% of 
severe patients achieved PASI 75 and significant reduction of BSA levels after 15 days of treatment.
Conclusion: EP2311454 treatment, composed by antioxidant molecules, proved to be antiinflammatory in vitro and showed efficacy in 
patients with mild to severe psoriasis, as demonstrated by a significant decrease in PASI, BSA and DLQI levels.
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oxidants and antioxidants in favour of the oxidants, leading to a 
disruption of redox signalling and promoting molecular damage 
[5]. Different studies have associated the antioxidant properties 
of specific compounds with anti-inflammatory effects in psoriasis, 
suggesting a potential role for these compounds as therapeutic 
tools [6,7]. Using well characterized compounds, the “Ignacio 
Umbert Dermatology Institute” (IUDI) has developed topical 
treatments that differ from the standards. The therapy used for 
psoriasis (European patent number EP2311454) is a combination 
of well-established drugs and a set of compounds with antioxidant 
activity (indomethacin, ascorbyl palmitate, taurine, curcumin and 




Raw264.7 macrophages (American Type Culture Collection, 
Manassas, VA, USA) were used for the in vitro analysis of the 
anti-inflammatory activity of specific compounds. Raw264.7 cells 
were stably transfected with a mammalian expression vector 
encoding human peroxisome proliferator-activated receptor-
gamma (PPARG). Cell transfection was performed using Superfect 
reagent (Qiagen, Valencia, CA, USA) following the manufacturer’s 
recommendations. Two days after transfection, stable 
transfectants were selected by culturing the cells for two weeks in 
DMEM (Biowest, Nuaille, France) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Biosera, Boussens, France) 
and geneticin (Thermo Fisher Scientific, Rockford, IL, USA). A 
clone of cells was selected and the expression of human PPARG 
was verified by both quantitative real time-PCR and by western 
blotting using rabbit polyclonal antibodies against hPPARG (Cell 
Signaling, Danvers, MA, USA). 
Treatment: Interferon-gamma (IFN-γ) was obtained from 
Thermo Fisher Scientific (Rockford, IL, USA). Indomethacin, 
ascorbyl palmitate, taurine, curcumin and resveratrol are the 
main components of EP2311454 treatment (EP2311454 patent). 
Ascorbic acid 6-palmitate was purchased from Abcam (Cambridge, 
UK) and the rest of compounds were obtained from Sigma-Aldrich 
(Saint Louis, MO, USA). All of them were dissolved according to the 
manufacturer’s instructions. Treatment of Raw 264.7 cells with 
antioxidant compounds and/or IFN-γ was performed in DMEM 
supplemented with 1% heat-inactivated FBS.
Determination of gene expression: Cells were washed 
twice in cold PBS and total RNA was extracted using Tri reagent 
(Sigma-Aldrich) as recommended by the manufacturer. For cDNA 
synthesis, 1µg of total RNA was subjected to reverse transcription 
using M-MLV Reverse transcriptase RNase H Minus, Point Mutant, 
oligo(dT)15 primer and PCR nucleotide mix (Promega, Fitchburg, 
WI, USA). Quantitative real time (rt)-PCR was performed using the 
Power SYBR Green Reagent Kit (Applied Biosystems, Foster City, 
CA) following the manufacturer’s recommendations. The primers 
used in this study are shown in (Table 1). Annealing for all primers 
was performed at 60ºC for 30s. Real-time monitoring of PCR 
amplification was performed using the ABI Prism 7900 Sequence 
Detection System (Applied Biosystems). Data were expressed as 
relative mRNA levels normalized to ribosomal L14 expression.
Table 1: Primers used for quantitative real time-PCR determinations.






Selection: A group of 35 patients, (5 mild, 9 moderate and 21 
severe psoriasis) both males and females, previously diagnosed 
with psoriasis were included in the study. Patients were eligible 
to participate in the trial if they were at least 18 years of age and 
had been diagnosed with mild to severe psoriasis. Individuals 
with allergies or pregnant women were not included in the study. 
Patients provided written, informed consent.
Monitoring: For evaluation, a total of six visits were planned 
at 0, 15, 30, 45, 52 and 60 days from the start of treatment. 
Photographs were taken and physical and dermatological 
examinations were performed. 
Treatment: Patients were instructed to use 2 g of cream per 
application and perform three applications per day (every 8h). 
The cream was placed first on the fingertips and then distributed 
homogeneously in small sub-portions on the affected area. 
Circular motions were performed until the cream was completely 
absorbed by the skin. In addition, 0.5 g curcumin per day was 
administered orally dissolved in soups.
Evaluation: The effectiveness of the therapy on disease 
severity was scored using two objective outcome measurements, 
namely Psoriasis Area Severity Index (PASI) and Body Surface Area 
(BSA). PASI was calculated for all patients. Each site (head, trunk, 
upper and lower limbs) was evaluated separately for erythema, 
infiltration and desquamation and the data were summed to 
calculate final PASI, as described previously (“Guideline on clinical 
investigation of medicinal products indicated for the treatment of 
psoriasis” European Medicines Agency Evaluation of Medicines for 
Human Use, 2014). Additionally, the quality of life was measured 
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using the Dermatology Life Quality Index (DLQI). The following 
criteria was used to determine the severity of psoriasis: mild to 
moderate psoriasis: BSA < 10% or PASI < 10; moderate psoriasis: 
10% < BSA > 20% or 10 ≤ PASI ≥ 20; severe psoriasis: BSA > 20% 
or PASI > 20. The efficacy of treatment was evaluated through PASI 
75, which represents the percentage of patients achieving a 75% 
or more reduction in their PASI score from baseline.
Statistical analysis
Results are presented as mean ± SEM. GraphPad Prism 
program (Prism 4.0, Graphpad Software Inc) and SPSS software 
(IBM) were used for statistical analysis of the human and in 
vitro studies, respectively. In Figure 3, a two-tailed Student t-test 
was used for paired comparisons. Differences were considered 
significant if the p-value < 0.05.
Results
Clinical evaluation of EP2311454 in psoriasis patients 
Patients treated with EP2311454 have a positive response to 
treatment; examples of target-lesions improvement are shown in 
Figure 1, in which the patients were recovered after 15 (Figure 1a) 
or 60 days (Figure 1b) of treatment. Quality of life before and after 
the treatment was assessed by determining the DLQI index and 
results indicate that EP2311454 improves the outcome. 95% of 
patients treated show significant amelioration of the disease, with 
an average reduction of 80% reduction in DLQI levels after 60 days 
of treatment (Figure 1c). Besides DLQI, two other parameters, 
PASI and BSA, were evaluated at baseline and at different time 
points after the start of treatment (0, 15, 30, 45 and 60 days). 
PASI values decreased significantly, with clear effects already at 
day 15 of treatment (Figure 2a). When taking into account global 
improvement, 100% of patients, including patients with moderate 
to severe psoriasis, achieved at least 50% improvement in PASI 
(PASI 50) (Figure 2b) Furthermore, the proportions of patients 
who achieved PASI 75 was 80% in the mild to moderate group 
and 100% in the severe group of patients. Interestingly, 70% of 
EP2311454-treated severe patients reached PASI 90 (Figure 2b). 
On the other hand, significant reduction of BSA values compared to 
baseline were also observed in patients treated with EP2311454 
(Figure 2c). 
Figure 1:  Progression of psoriatic lesions under EP2311454 treatment. a) Picture of the back of a patient with severe psoriasis before (left) 
and after (right) treatment. b) Picture of the arm of a moderate patient with psoriasis before (left) and after (right) treatment. c) DLQI levels 
pre and posttreatment, 60 days. Treatment reduces significantly DLQI levels n=22 ****p< 0.0001 versus pretreatment (paired Student t-test).
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Figure 2:  Therapeutic efficacy of treatment in patients with psoriaris. a) Psoriasis area severity index (PASI) quantifications during treatment. 
b) Percentage of patients with 50% reduction, 75% reduction or 90% reduction in the Psoriasis Area and Severity Index (PASI 50, PASI 75 
and PASI 90, respectively), compared with baseline, after treatment with EP2311454 The patients were divided in three groups according to 
the severity of psoriasis before treatment: mild (n=5), moderate (n=9) and severe (n=21). c) Body Surface area (BSA) quantifications during 
treatment. Treatment reduces significantly PASI and BSA levels (n=22) ****p<0.0001, ***p<0.001 versus pre-treatment. Paired Student 
t-test.
In vitro effects of EP2311454 components on 
macrophage activation by IFN-γ 
Raw264.7 macrophages expressing human PPAR-γ were pre-
treated with different combinations of the antioxidant compounds 
in EP2311454 treatment and then stimulated with IFN-γ for 6h 
(Figure 3). Changes in gene expression were analyzed through 
quantitative rt-PCR (Figure 3a). The percentage of repression was 
calculated in order to compare the effectiveness of combinations 
of compounds (Figure 3b). In Figure 3b, positive values indicate 
repression (inhibition), whereas negative values indicate induction 
(increase) in comparison with the levels of expression in IFN-γ-
treated cells. In these conditions, the combined use of curcumin 
and ascorbic acid 6-palmitate resulted in synergistic inhibitory 
effects on the expression of the enzymes cyclooxygenase 2 (Cox2) 
and nitric oxide synthase 2 (Nos2), and the chemokine Cxcl9, 
whereas the expression of tumor necrosis factor-alpha (Tnfα) and 
C-C motif chemokine ligand 2 (Ccl2/MCP-1) was unaffected (data 
not shown). Moreover, the use of indomethacin further enhanced 
the inhibitory effects of curcumin and ascorbic acid 6-palmitate on 
Nos2 and Cox2 expression.
Discussion
Given the limitations of current treatments for psoriatic 
diseases and the evidence that reactive oxygen species-mediated 
oxidative stress contributes to the pathogenesis of inflammatory 
skin disorders, including psoriasis [8,9], new approaches have 
been designed in the last few years based on the pharmacological 
use of antioxidant molecules, such as epigallocatechin-3-gallate [6] 
and curcumin [10]. Antioxidant compounds have demonstrated 
efficacy as therapeutical treatments also against other chronic 
inflammatory diseases [11]. Although the clinical application of 
antioxidants for skin inflammatory disorders is not widespread, 
we decided to test their efficacy in psoriasis using a combination 
of antioxidant compounds. In particular, EP2311454 combines 
compounds with both antioxidant and antiinflammatory activity 
and traditional drugs in order to ameliorate the symptoms of 
psoriasis. The main components in EP2311454 are resveratrol, 
taurine and ascorbyl-L-palmitate, previously defined as 
antioxidant compounds in humans, and indomethacin which is 
anti-inflammatory in low doses [12].
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Figure 3:  Effects of combined treatment with low doses of antioxidants. The cells were treated with IFN-γ (5 ng/ml) in the presence or 
absence of the indicated antioxidants: indomethacin (Indo, 5 µM), ascorbic acid 6-palmitate (Asc. Palm, 25 µM), and/or curcumin (10 µM). 
mRNA expression levels of several genes involved in the macrophage response to IFN-γ are represented a) The graphics show normalized 
values of gene expression relative to ribosomal L14 expression levels obtained from three to six independent experiments (depending on 
the gene studied). ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 versus IFN-γ. Two-tailed Student t-test. b) The % of repression of each 
combination of compounds (over the levels induced by IFN-γ was calculated for those genes whose expression was inhibited by one or 
more antioxidants.
EP2311454 treatment efficiency was evaluated in patients 
with psoriasis, resulting in significant decrease of BSA, DLQI 
and PASI levels. This analysis confirmed that EP2311454 is 
efficacious for the treatment of psoriasis. PASI 75 response rates 
for individuals treated with EP2311454 is 100% for severe 
patients and 80% for mild to moderate patients. The effect 
was evident at the earliest assessment (15 days). The results 
presented here are in line with other studies that suggested that 
moderate to severe psoriatic plaques should show a therapeutic 
response to orally administered curcuma [13] or to antioxidant 
compounds, pointing out that adjuvant therapies are promising 
solutions for increasing the efficacy of traditional drugs against 
psoriasis [14,15]. In order to understand the cellular mechanisms 
underlying the efficacy of EP2311454, the effects of individual 
and combined components within this formula were tested in a 
model of macrophage inflammatory response in vitro. Analysis of 
the combined action of indomethacin with other antioxidants has 
shown that the efficacy of some combinations is greater than the 
efficacy of individual compounds. The combined use of curcumin 
and ascorbic acid 6-palmitate resulted in synergistic inhibitory 
effects on the expression of Cox2, Nos2 and Cxcl9, and the presence 
of indomethacin in the combination further increased repression 
of Nos2 and Cox2. These results suggest that the combination 
of curcumin and ascorbic acid 6-palmitate together with 
indomethacin have increased anti-inflammatory capacity than the 
antioxidants individually. Together with the clinical results, these 
data suggest that EP2311454 treatment is a promising strategy to 
ameliorate the clinical symptoms of psoriasis.
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